184 related articles for article (PubMed ID: 7921465)
41. Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension.
Martin I; Humbert M; Marfaing-Koka A; Capron F; Wolf M; Meyer D; Simonneau G; Anglés-Cano E
Blood Coagul Fibrinolysis; 2002 Jul; 13(5):417-22. PubMed ID: 12138369
[TBL] [Abstract][Full Text] [Related]
42. Fibrinolytic activity in laparoscopic cholecystectomy.
Martinez-Ramos C; Lopez-Pastor A; Núñez-Peña JR; Ruiz-Caravaca ML; Ruiz de Gopegui M; Sanz-López R; Jorgensen TW; Tamames-Escobar S
J Laparoendosc Adv Surg Tech A; 1998 Dec; 8(6):417-23. PubMed ID: 9916595
[TBL] [Abstract][Full Text] [Related]
43. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.
Olman MA; Marsh JJ; Lang IM; Moser KM; Binder BR; Schleef RR
Circulation; 1992 Oct; 86(4):1241-8. PubMed ID: 1394930
[TBL] [Abstract][Full Text] [Related]
44. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction.
Chandler WL; Stratton JR
Am J Clin Pathol; 1994 Aug; 102(2):248-52. PubMed ID: 8042597
[TBL] [Abstract][Full Text] [Related]
45. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
[TBL] [Abstract][Full Text] [Related]
46. Thrombotic biomarkers and left ventricle characteristics as short-term predictors of thrombotic events in patients hospitalized for acute decompensated heart failure.
Aispuru GR; Clavier MM; Cardone AJ; Gilberto DO; Barousse AP
Eur J Intern Med; 2012 Sep; 23(6):545-51. PubMed ID: 22863433
[TBL] [Abstract][Full Text] [Related]
47. Enhanced levels of tissue-type plasminogen activator in borderline hypertension.
Wall U; Jern C; Bergbrant A; Jern S
Hypertension; 1995 Nov; 26(5):796-800. PubMed ID: 7591020
[TBL] [Abstract][Full Text] [Related]
48. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension.
Altman R; Scazziota A; Rouvier J; Gurfinkel E; Favaloro R; Perrone S; Fareed J
Clin Cardiol; 1996 Jul; 19(7):549-54. PubMed ID: 8818435
[TBL] [Abstract][Full Text] [Related]
49. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH
Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039
[TBL] [Abstract][Full Text] [Related]
50. The effects of chronic smoking on the fibrinolytic potential of plasma and platelets.
Simpson AJ; Gray RS; Moore NR; Booth NA
Br J Haematol; 1997 Apr; 97(1):208-13. PubMed ID: 9136967
[TBL] [Abstract][Full Text] [Related]
51. Changes and significance of the fibrinolytic system following two pulmonary thromboembolisms in a rabbit model.
Liu DC; Duan B; Zhao MN; Wu L; Cao YZ; Liu NB; Xue Z; He ZH; Mi J
J Physiol Pharmacol; 2024 Apr; 75(2):137-144. PubMed ID: 38736261
[TBL] [Abstract][Full Text] [Related]
52. Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schönlein purpura.
Besbas N; Erbay A; Saatçi U; Ozdemir S; Bakkaloglu A; Ozen S; Topaloglu R
Clin Exp Rheumatol; 1998; 16(1):95-8. PubMed ID: 9543574
[TBL] [Abstract][Full Text] [Related]
53. Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin.
Carmichael AR; Tate G; King RF; Sue-Ling HM; Johnston D
Pathophysiol Haemost Thromb; 2002; 32(1):40-3. PubMed ID: 12214162
[TBL] [Abstract][Full Text] [Related]
54. Type 2 Diabetes and Cardiovascular Factors Contrasted with Fibrinolysis Disorders in the Blood of Patients with Peripheral Arterial Disease.
Wieczór R; Wieczór AM; Kulwas A; Rość D
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31336615
[No Abstract] [Full Text] [Related]
55. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
[TBL] [Abstract][Full Text] [Related]
56. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.
Kopeikina LT; Kamper EF; Koutsoukos V; Bassiakos Y; Stavridis I
Clin Rheumatol; 1997 May; 16(3):254-60. PubMed ID: 9184262
[TBL] [Abstract][Full Text] [Related]
57. [Changes of blood coagulative and fibrinolytic systems and functions of pulmonary vascular endothelium in patients with pulmonary thromboembolism].
Pang BS; Wang C; Zhai ZG; Yang YH; Mao YL; Huang XX; Zhu J
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Oct; 28(10):714-6. PubMed ID: 16255959
[TBL] [Abstract][Full Text] [Related]
58. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):75-9. PubMed ID: 10600272
[TBL] [Abstract][Full Text] [Related]
59. The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Snieder H; Navis G; Vaughan DE; van Gilst WH; Moore JH
Hum Genet; 2007 Nov; 122(3-4):275-81. PubMed ID: 17593394
[TBL] [Abstract][Full Text] [Related]
60. Plasma coagulation profiles in patients with severe primary pulmonary hypertension.
Hoeper MM; Sosada M; Fabel H
Eur Respir J; 1998 Dec; 12(6):1446-9. PubMed ID: 9877507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
